The role of gut microbiome and TLR4 in chemotherapy-induced diarrhea
Using MammaPrint to select patients who may not need adjuvant chemotherapy – the results of MINDACT
Biosimilars and the exciting results of the REFLECTIONS trial
Durvalumab: the new standard of care for NSCLC?
Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trial